Solid cancers after allogeneic hematopoietic cell transplantationJ. Douglas Rizzo, H. Joachim Deeg, Rochelle E. Curtis et al.|Blood|2008Cited by 489
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantationOla Landgren, Rochelle E. Curtis, Ethel S. Gilbert et al.|Blood|2009Cited by 400
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell TransplantationAntonio Palumbo, Robert Z. Orlowski, S. Vincent Rajkumar et al.|Journal of Clinical Oncology|2014Cited by 384
GPRC5D-Targeted CAR T Cells for MyelomaSham Mailankody, Eric L. Smith, Xiuyan Wang et al.|New England Journal of Medicine|2022Cited by 383
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple MyelomaNeha Korde, Ola Landgren, Mark Roschewski et al.|JAMA Oncology|2015Cited by 309